Emerging Infectious Disease ISSN: 1080-6059

Antibody Response to Pneumocystis jirovecii

Kieran R. Daly*†, Laurence Huang‡, Alison Morris§, Judy Koch*†, Kristina Crothers‡¶, Linda Levin†, Shary Eiser‡, Supriya Satwah†, Patrizia Zucchi‡#, and Peter D. Walzer*†

Author affiliations: *Veterans Affairs Medical Center, Cincinnati, Ohio, USA; †University of Cincinnati, Cincinnati, Ohio, USA; ‡University of California, San Francisco, California, USA; §University of Southern California, Los Angeles, California, USA; ¶Yale University School of Medicine, New Haven, Connecticut, USA; #University of Pavia, Pavia, Italy

Main Article

Figure

Figure. Sequential serum antibody responses to major surface glycoprotein C (MsgC) in HIV-positive patients with pneumocystosis. Patients 1 and 2: antibody levels rose from 21.6 and 3.2 at baseline (point 0) to 55.8 and 23.1 at 3–4 weeks and fell to 36.9 and 4.3, respectively, at 7–8 weeks; patient 3: antibody level showed few changes from baseline until it rose to 77.1 at 5–6 weeks; patient 4: antibody level remained at baseline level of 1.0 throughout.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.